$825.45
0.54%
NYSE, Oct 24, 10:06 pm CET
ISIN
US5324571083
Symbol
LLY

Eli Lilly and Company Stock price

$825.45
+83.60 11.27% 1M
-34.28 3.99% 6M
+53.45 6.92% YTD
-65.87 7.39% 1Y
+477.55 137.27% 3Y
+683.75 482.53% 5Y
+746.34 943.42% 10Y
+774.67 1,525.54% 20Y
NYSE, Closing price Fri, Oct 24 2025
+4.41 0.54%

Key metrics

Basic
Market capitalization
$781.3b
Enterprise Value
$817.6b
Net debt
$36.4b
Cash
$3.5b
Shares outstanding
946.8m
Valuation (TTM | estimate)
P/E
53.8 | 36.0
P/S
14.7 | 12.5
EV/Sales
15.4 | 13.1
EV/FCF
negative
P/B
42.8
Dividends
DPS
$5.20
Yield 1Y | 5Y
0.6% | 1.0%
Growth 1Y | 5Y
15.0% | 15.1%
Payout 1Y | 3Y
44.4% | 55.9%
Increased
10 Years
Financials (TTM | estimate)
Revenue
$53.3b | $62.3b
EBITDA
$24.3b | $27.6b
EBIT
$22.4b | $25.8b
Net Income
$13.8b | $21.7b
Free Cash Flow
$-50.2m
Growth (TTM | estimate)
Revenue
36.8% | 38.3%
EBITDA
61.8% | 46.7%
EBIT
67.1% | 51.3%
Net Income
88.0% | 105.2%
Free Cash Flow
98.6%
Margin (TTM | estimate)
Gross
82.6%
EBITDA
45.7% | 44.3%
EBIT
42.1%
Net
25.9% | 34.9%
Free Cash Flow
-0.1%
Financial Health
Equity Ratio
18.0%
Return on Equity
74.6%
ROCE
36.3%
ROIC
23.0%
Debt/Equity
2.2
More
EPS
$15.3
FCF per Share
$-0.1
Short interest
0.9%
Employees
47k
Rev per Employee
$960.0k
Show more

Is Eli Lilly and Company a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,040 stocks worldwide.

Eli Lilly and Company Stock Analysis

Unlock Scores for Free

Analyst Opinions

35 Analysts have issued a Eli Lilly and Company forecast:

26x Buy
74%
9x Hold
26%

Analyst Opinions

35 Analysts have issued a Eli Lilly and Company forecast:

Buy
74%
Hold
26%

Financial data from Eli Lilly and Company

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
53,258 53,258
37% 37%
100%
- Direct Costs 9,247 9,247
23% 23%
17%
44,012 44,012
40% 40%
83%
- Selling and Administrative Expenses 9,746 9,746
25% 25%
18%
- Research and Development Expense 11,826 11,826
16% 16%
22%
24,332 24,332
62% 62%
46%
- Depreciation and Amortization 1,893 1,893
17% 17%
4%
EBIT (Operating Income) EBIT 22,439 22,439
67% 67%
42%
Net Profit 13,800 13,800
88% 88%
26%

In millions USD.

Don't miss a Thing! We will send you all news about Eli Lilly and Company directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eli Lilly and Company Stock News

Positive
Seeking Alpha
about 18 hours ago
October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound and Mounjaro. Since my article was published on September 8, Eli Lilly's stock price has risen by 13.1%. On October 24th, Eli Lilly surprised me by announcing its acquisition of Adverum Biotechnologies, a developer of gene therapies for the treatment of ocular diseases, for...
Neutral
Seeking Alpha
about 19 hours ago
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Neutral
Business Wire
one day ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Adverum Biotechnologies, Inc. (NasdaqCM: ADVM) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Adverum will receive $3.56 per share in cash plus one no...
More Eli Lilly and Company News

Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Head office United States
CEO David Ricks
Employees 47,000
Founded 1876
Website www.lilly.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today